Global Custom Antibody Market Overview
The Custom Antibody Market Size was valued at USD 0.16 billion in 2022 and is projected to grow from USD 0.17 Billion in 2023 to USD 0.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8% during the forecast period (2023 - 2030). Growing demands for personalized medicine and increased partnerships and collaborations for developing custom antibodies are the key market drivers of custom antibody.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
Custom Antibody Market Trends
- Growing companies offering R&D services for custom antibodies to drive market growth
Custom antibodies can be used for both qualitative and quantitative immune detection. Custom antibodies outperform regularly cultured antibodies in terms of selectivity and specificity. Moreover, these custom antibodies are relatively easy to produce compared to other antibodies, making them a popular choice for various research studies. Customized antibodies can be produced in hamsters, mice, or rats to meet host requirements. The adaptive immune system produces antibodies in response to invading pathogens. The offending virus, bacteria, or other molecules are locked and unlocked by the antibody's specific lock and critical recognition. Researchers worldwide are conducting various types of research focused on using this physiological process of the human body to produce unique antibodies in response to antigens that describe particular infections or medical conditions. Companies offer a diverse range of antibodies based on the researcher's needs.
The industry's growing research efforts in biology and the life sciences are driving factors for market expansion. Patients' rapidly increasing awareness of the efficacy of the drugs is also contributing to market growth. Moreover, the growing adoption of immunotherapeutic and targeted therapy due to their efficacy and common complications drives the custom antibody market CAGR growth. Customized medications have gained popularity for treating cancer and other chronic diseases. As a result, the utilization of personalized antibodies is increasing, fueling market growth. For example, MonoRab, a novel rabbit mAB, was introduced by GenScript in June 2021. The technologies involved are mAB sequencing and hybridoma. It is more affine and has higher specificity in a variety of applications. Growing government funding and support, advancements in biotechnology research, shifting disease profiles, and expanded public and private partnerships contribute to custom antibody market revenue growth.
Custom Antibody Market Segment Insights
Custom Antibody Service Insights
Based on service, the market segments of custom antibody includes antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody development segment held the majority share in 2022, contributing around ~42-45% to the custom antibody market revenue owing to the expansion of biotechnology and biopharmaceutical companies. The growing emphasis of researchers on high-quality, specially designed antibodies for reproducibility, which can be crippled when using commercially available antibodies, can be attributed to the large share of this segment. Additionally, increased R&D activities for developing targeted antibodies are expected to drive market expansion over the projection period.
Figure 1: Custom Antibody Market, by Service, 2022 & 2030 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
Custom Antibody Source Insights
Based on the source, the custom antibody market segmentation includes mice and others. The mice segment dominated the market in 2022 and is likely to be the faster-growing segment during the forecast period, 2022-2030. Mice are the most used hosts to produce research-use antibodies. Compared to other experimental sources, mice have lower feeding costs and are easier to maintain and handle due to their small size. They produce human-like IgA, IgE, IgD, IgG, and IgM antibody isotypes. In addition, laboratory mice can elicit a robust immune response to various antigens, including highly homologous human proteins. Besides, certain medications that are illegal to use on humans can be used legally on mice with results comparable to humans. Mice have previously played an essential role in discovering and pre-clinical evaluation of monoclonal antibodies, owing to the pharmaceutical industry's rapid production of therapeutic antibodies.
October 2022: Taconic Biosciences has announced the release of the FcResolv NOG portfolio, an immunodeficient mice model lacking murine Fc gamma receptors. The product enables scientists to evaluate potential candidates without interfering with lingering murine Fc gamma receptor activity, which the company claims is anticipated to promote antibody-based therapeutic approaches during the preclinical stage for the custom antibody industry.
Custom Antibody Research Area Insights
Research areas have bifurcated the custom antibody market data into oncology, neurobiology, infectious diseases, immunology, and others. The oncology segment dominated the market in 2022 and is predicted to be the faster-growing segment during the forecasted period 2022-2030. The rising cancer incidence rate and advancements in personalized treatment are projected to be key growth drivers in the oncology application segment of the custom antibodies market. Oncology is the most innovative therapeutic field regarding clinical trial activity, the number of companies investing in therapeutic applications, clinical advancement, the introduction of novel active substances, and the cost of these drugs. Cancer is one of the most prevalent causes of mortality, which has resulted in advances in cancer research and an increase in the proportion of therapeutic mAbs in clinical trials and research. This factor is responsible for a significant proportion of the oncology segment market growth.
Custom Antibody Type Insights
The custom antibody industry has been segmented based on type into monoclonal, polyclonal, recombinant, and other custom antibodies. Monoclonal held the most prominent segment share in 2022. Monoclonal antibodies are one of the most effective biologics used for various purposes. These compounds' high selectivity, specificity, and binding affinity frequently make them valuable, and researchers in all research studies prefer them. Additionally, monoclonal antibodies are molecules created in a lab that act as substitutes and can boost, restore, mimic, or alter the immune system's attack on undesirable cells, such as cancer cells. They are also designed to bind to antigens that are more numerous on the surface of cancer cells than on the surface of healthy cells. Furthermore, polyclonal antibodies have advantages such as easy storage, high affinity, stability, and suitability for western and ELISA blotting technologies.
Custom Antibody End User Insights
Based on end users, the custom antibody industry has been segmented into hospitals & clinics, academic & research institutes, contract research organizations, and biotechnology companies. Biotechnology companies held the highest segment revenue share in 2022. This is attributed to the growing demand for specific antibodies for drug discovery and development, genome and bioinformatics research development, and the expansion of research and development efforts in multiple therapeutic fields. An antibody is a protein naturally produced by the immune system in response to an infection. A monoclonal antibody is a substance developed in a lab that imitates or boosts the immune system's defenses against an adversary like cancer or an infection. Monoclonal antibodies benefit over other infection treatment methods in that they are created to directly target a crucial element of the infectious process.
Custom Antibody Regional Insights
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Custom Antibody market accounted for USD 0.073 billion in 2022 and is projected to exhibit a significant CAGR growth over the study period. The North American region's dominance can be attributed to increased investments in the development of structure-based drug designs, expanded genomics and proteomics research, increased demand for high-quality research tools for data reproducibility, rising interest in the development of antibody-based therapeutics, and the presence of several international players in this region. Also, the region has a vast number of clinical research organizations that are associated with the development of new therapeutic antibodies. These have accelerated progress in the biotechnology sector, increasing demand for high-throughput technology solutions in laboratory workflows. North America's market dominance is anticipated to remain unchallenged during the forecast period due to the region's rapid adoption of cutting-edge technological solutions, significant investments in R&D, and rising wages for highly qualified workers.
Further, the major countries studied in the market report are the U.S., Germany, Canada, the UK, Italy, France, Spain, China, Japan, Australia, India, South Korea, and Brazil.
Figure2: CUSTOM ANTIBODY MARKET SHARE BY REGION 2022 (%)
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
European custom antibody market accounts for the second-largest market share. Factors such as increased research expenses, technological advancement, a decline in human health, and the need for innovative and effective therapies all contribute to this region's growth. According to Capra Science, a European company specializing in custom antibody production, llama-derived nanobodies may have therapeutic applications in Parkinson's disease. As a result, increased R&D activities drive demand for custom antibodies and revenue growth in the European market. Further, the German market of custom antibody held the largest market share, and the UK market of custom antibody was the fastest-growing market in the European region.
The Asia-Pacific Custom Antibody Market is projected to grow at the fastest CAGR between 2022 and 2030. This is primarily due to increased government and business investment, biotechnology research expansion, and awareness of personalized therapeutics. Due to economic developments, China and India receive more investments from international investors. Similarly, regional players are expanding their presence in the market for custom antibodies. Moreover, the China market of custom antibody held the largest market share, and the Indian market of custom antibody was the fastest-growing market in the Asia-Pacific region.
Custom Antibody Key Market Players & Competitive Insights
Major market players will likely assist end users with the development process by advancing technology in their workflow. Key custom antibody industry players now have several opportunities to profit from the ongoing demand for custom antibodies from numerous end users. The custom antibody market major players, including Genscript, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Merck Group, and others, are working to increase market demand by investing in research and development.
The custom antibody industry is relatively consolidated, with a small number of large and medium-sized players accounting for most of the market revenue. Major players are implementing various market development strategies, including mergers and acquisitions, strategic agreements, and contracts, increasing R&D activities, and developing, testing, and introducing more effective custom antibody products. In recent years, the custom antibody industry has supplied some of the most significant benefits to recombinant antibodies.
Thermo Fisher Scientific Inc is an American manufacturer and distributor of scientific instruments, reagents, consumables, and software services. Thermo Fisher Scientific and BATL at Northeastern University signed a collaboration agreement in 2020 to advance analytical capabilities and drive innovation in the biopharmaceutical industry in areas such as personalized medicine, monoclonal custom antibodies, and gene & cell therapies.
Also, Absolute Antibody Ltd is a company that specializes in custom antibody sequence analysis, expression, and engineering. The business announced in August 2022 that it would expand its production facility by adding lab space and funding automated technology like next-generation sequence analysis, purification, and expression. The expansion is anticipated to enhance the recombinant antibody production process.
Key Companies in the market of custom antibody include
-
Thermo Fisher Scientific Inc
-
Genscript
-
Abcam PLC
-
Merck Group
-
Bio-Rad Laboratories Inc
-
Cell Signaling Technology Inc
-
Agilent Technologies Inc
-
Biolegend Inc
-
Rockland Immunochemicals Inc
-
Promab Biotechnologies Inc
Custom Antibody Industry Developments
January 2023:Adimab, a company that discovers and optimizes monoclonal and bispecific antibodies, announced partnerships with 11 companies in 2022. As of January 2023, the company had collaborated with over 105 businesses to discover therapeutics.
July 2022:Bio-Rad Laboratories Inc has released a new line of custom antibodies to target membrane antibodies and antigens. The new product line includes monoclonal, polyclonal, and recombinant antibodies that can be used for various applications such as ELISA, Western blotting, immunohistochemistry, and flow cytometry.
June 2021:SunRock Biopharma and GenScript have partnered to create therapeutic antibody candidates. SunRock Biopharma will receive assistance from GenScript in developing cell lines, GMP drug processes, manufacturing pharmaceutical products, and antibody research and development.
Custom Antibody Market Segmentation
Custom Antibody Service Outlook
Custom Antibody Source Outlook
Custom Antibody Research Area Outlook
-
Oncology
-
Neurobiology
-
Infectious Diseases
-
Immunology
-
Others
Custom Antibody Type Outlook
-
Monoclonal Antibodies
-
Polyclonal Antibodies
-
Recombinant Antibody
-
Other Custom Antibodies
Custom Antibody End Users Outlook
Custom Antibody Regional Outlook
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 0.16 billion |
| Market Size 2023 |
USD 0.17 billion |
| Market Size 2030 |
USD 0.3 billion |
| Compound Annual Growth Rate (CAGR) |
9.8% (2023-2030) |
| Base Year |
2022 |
| Market Forecast Period |
2023-2030 |
| Historical Data |
2018 - 2021 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Market Competitive Landscape, Revenue Forecast, Growth Factors, and Trends |
| Segments Covered |
Service, Source, Research Area, Type, End Users, and Region |
| Geographies Covered |
Europe, North America, Asia Pacific, and the Rest of the World |
| Countries Covered |
The U.S, Germany, Canada, U.K., Italy, France, Spain, Japan, China, Australia, India, South Korea, and Brazil |
| Key Companies Profiled |
Thermo Fisher Scientific Inc, Genscript, Abcam PLC, Merck Group, Bio-Rad Laboratories Inc, Cell Signaling Technology Inc, Agilent Technologies Inc, Biolegend Inc, Rockland Immunochemicals Inc, Promab Biotechnologies Inc |
| Key Market Opportunities |
Increasing demand from both pharmaceutical and biotechnology companies for therapeutics based on antibodies Expanding the availability of customized services for the creation of custom antibodies |
| Key Market Dynamics |
Growing demands for personalized diagnostic and treatments Rising research activity in the life sciences industry |
Custom Antibody Market Highlights:
Frequently Asked Questions (FAQ) :
The custom antibody market size was valued at USD 0.16 Billion in 2022.
The market is likely to grow at a CAGR of 9.8% during the forecast period, 2023-2030.
North America had the largest share of the market.
The key players in the market are Thermo Fisher Scientific Inc, Genscript, Abcam PLC, Merck Group, Bio-Rad Laboratories Inc, Cell Signaling Technology Inc, Agilent Technologies Inc, Biolegend Inc, Rockland Immunochemicals Inc, Promab Biotechnologies Inc.
The antibody development category dominated the market in 2022.
Biotechnology companies had the largest revenue share of the market.
